A randomized, double-blind, placebo and active-controlled efficacy and safety study of SSR240600C in patients with overactive bladder (OAB) or urge urinary incontinence (UUI).

Trial Profile

A randomized, double-blind, placebo and active-controlled efficacy and safety study of SSR240600C in patients with overactive bladder (OAB) or urge urinary incontinence (UUI).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2012

At a glance

  • Drugs SSR 240600 (Primary) ; Tolterodine
  • Indications Overactive bladder; Urge incontinence
  • Focus Therapeutic Use
  • Acronyms MILADY
  • Most Recent Events

    • 01 Feb 2012 Actual patient number is 118 according to ClinicalTrials.gov.
    • 01 Feb 2012 Actual end date (May 2006) added as reported by ClinicalTrials.gov.
    • 22 Sep 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top